NDAORALTABLET
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
15
Data completeness
5/8 — Partial
HEMICLOR (chlorthalidone) by R-Pharm US is long-acting oral diuretic with antihypertensive activity. First approved in 2025.
Drug data last refreshed 11h ago · AI intelligence enriched 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEMICLOR (chlorthalidone) is a long-acting oral thiazide-like diuretic approved in March 2025 for hypertension management. It works by inhibiting sodium and chloride reabsorption in the ascending limb of Henle's loop, reducing extracellular fluid volume and cardiac output to lower blood pressure. Chlorthalidone is a potent antihypertensive agent with a prolonged duration of action compared to traditional thiazides.
Growth19.0 years to LOE
Recent NDA approval positions HEMICLOR in early growth phase with opportunity for field team expansion and market development activities.
Mechanism of Action
long-acting oral diuretic with antihypertensive activity. Chlorthalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears to be the cortical diluting segment of the ascending limb of Henle's loop of the nephron. The diuretic effects of chlorthalidone…
Pharmacologic Class:
Thiazide-like Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Started Mar 2026
3,500 enrolled
Hypertension
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
Started Nov 2016
0Essential Arterial Hypertension
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
Started Nov 2016
0Essential Arterial Hypertension
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
Started Dec 2015
170 enrolled
Essential Hypertension
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Started Oct 2011
507 enrolled
Essential Hypertension
Worked on HEMICLOR at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.